HOME >> BIOLOGY >> NEWS
Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.

Dr. Dennis Slamon, whose laboratory and clinical research lead to the development of Herceptin, reported results of the Phase III study of more than 3,200 women Thursday at the 29th annual San Antonio Breast Cancer Symposium.

The three-armed study compared the standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT), an experimental regimen of Adriamycin and Carboplatin followed by Taxotere and one year of Herceptin (ACTH), and an experimental regimen of Taxotere and Carboplatin with one year of Herceptin (TCH).

The study tested Herceptin with and without Adriamycin, an anthracycline commonly used to treat breast cancer but one that, when paired with Herceptin, can cause permanent heart damage. Researchers wanted to determine whether they could provide a therapy as effective as ACTH without the resulting cardiac problems. The study, Slamon said, showed that the women who did not receive Adriamycin did just as well as those who did, and they experienced a five-fold decrease in significant heart toxicities compared to those who got Adriamycin. Also, some women in the ACTH arm developed leukemias, while none of the women on the non-Adriamycin arm did, Slamon said.

"This study demonstrates unequivocally that the best treatment for early stage HER-2 positive breast cancer is obtained with a non-anthracycline regimen, TCH, that avoids the significant cardiac damage found when Adriamycin is used with Herceptin," said Slamon, director of clinical/translational research at UCLAs Jonsson Cancer Center. "This trial should impact the way early stage breast cancer is treated, with TCH being considered the preferred option."

H
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
14-Dec-2006


Page: 1 2

Related biology news :

1. Gene profiling predicts resistance to breast cancer drug Herceptin
2. Herceptin plus chemotherapy improves disease-free survival in early breast cancer
3. Nanoparticles carry chemotherapy drug deeper into solid tumors
4. A faster way to recover from chemotherapy and marrow transplant
5. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
6. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
7. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
8. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
9. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
10. Massive gene screening points way to more effective chemotherapy
11. Researchers find the mechanism by which cells resist chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global voice recognition biometrics market to ... The report covers the present scenario and the growth ... calculate the market size, the report considers the revenue generated from ...
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... 2017  This Report analyzes the worldwide markets for Bioinformatics in ... provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , ... http://www.reportlinker.com/p04707099-summary/view-report.html ... Annual estimates and forecasts are provided for the period 2015 ...
(Date:2/20/2017)... Philadelphia, PA (PRWEB) , ... ... ... technologies to improve therapeutic success among radiotherapy patients, prevent chest wall collapses ... for femur fracture alignments will receive a total of $600,000 in funding ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
Breaking Biology Technology:
Cached News: